Form 4: Rhythm Pharma CTO Sells Shares After Option Exercise

Rhythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, sold 2,815 shares of common stock on October 28, 2025, following the exercise of stock options.

Summary

• Joseph Shulman, Chief Technical Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions on October 28, 2025.
• Shulman acquired 2,094 shares of common stock by exercising stock options at a price of $27.35 per share.
• He also acquired an additional 721 shares of common stock by exercising stock options at a price of $30.66 per share.
• Following these exercises, Shulman sold 2,815 shares of common stock at a weighted average price of $115.0089 per share.
• The sale price ranged from $115.00 to $115.08 per common stock.
• This sale was conducted pursuant to a Rule 10b5-1 instruction adopted on August 8, 2024.
• After these reported transactions, Shulman's direct beneficial ownership of common stock is 8,509 shares.
• Remaining derivative securities include 12,563 stock options with an exercise price of $27.35 and an expiration date of January 31, 2033.
• Additionally, 9,748 stock options remain with an exercise price of $30.66 and an expiration date of February 10, 2031.

Sentiment

Score: 5

Explanation: The filing reports a pre-planned insider sale under a 10b5-1 plan, which is a routine event for executive compensation and personal financial planning. While it represents a reduction in direct beneficial ownership, the pre-planned nature mitigates negative sentiment.

Positives

• Joseph Shulman realized significant gains by exercising stock options at prices of $27.35 and $30.66 and subsequently selling shares at a weighted average price of $115.0089.
• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to personal financial management rather than a discretionary sale based on new information.

Negatives

• The Chief Technical Officer's direct beneficial ownership of common stock decreased by 2,815 shares following the transactions, from 11,324 shares to 8,509 shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the reduction in direct beneficial ownership by a key executive, though the pre-planned nature of the sale under a Rule 10b5-1 plan typically mitigates concerns about insider sentiment.
• The transaction reflects a routine aspect of executive compensation and personal financial planning for the Chief Technical Officer.

Key Dates

Recommendation

The Form 4 details a pre-planned sale of shares by a Chief Technical Officer under a Rule 10b5-1 plan. This is a common practice for executives to manage personal finances and diversify holdings, often to cover taxes associated with option exercises. While it results in a reduction of direct beneficial ownership, the pre-scheduled nature of the transaction means it typically does not reflect a change in the executive's outlook on the company's future performance. Therefore, it does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' based solely on this filing.

Keywords

Rhythm Pharmaceuticals, RYTM, Form 4, Insider Trading, Stock Options, Executive Compensation, Joseph Shulman, 10b5-1 Plan, Biotechnology, Pharmaceuticals